| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 05-14-2024 | 03-31-2024 | 10-Q | |
| 2 | 03-26-2024 | 12-31-2023 | 10-K |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and maintains $...
The application was evaluated based on the positive clinical outcomes of KYV-101 in patients treated in Germany under a named-p...
HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral rati...
This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a dev...
Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option aft...
Kyverna Therapeutics shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate. ...
